Intracerebral Gene Therapy Using AAVrh.10-hARSA Recombinant Vector to Treat Patients with Early-Onset Forms of Metachromatic Leukodystrophy

Preclinical Feasibility and Safety Assessments in Nonhuman Primates

Michel Zerah, Françoise Piguet, Marie Anne Colle, Sylvie Raoul, Jack Yves Deschamps, Johan Deniaud, Benoit Gautier, Frédérique Toulgoat, Ivan Bieche, Ingrid Laurendeau, Dolan Sondhi, Mark M. Souweidane, Nathalie Cartier-Lacave, Philippe Moullier, Ronald Crystal, Thomas Roujeau, Caroline Sevin, Patrick Aubourg

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

No treatment is available for early-onset forms of metachromatic leukodystrophy (MLD), a lysosomal storage disease caused by autosomal recessive defect in arylsulfatase A (ARSA) gene causing severe demyelination in central and peripheral nervous systems. We have developed a gene therapy approach, based on intracerebral administration of AAVrh.10-hARSA vector, coding for human ARSA enzyme. We have previously demonstrated potency of this approach in MLD mice lacking ARSA expression. We describe herein the preclinical efficacy, safety, and biodistribution profile of intracerebral administration of AAVrh.10-hARSA to nonhuman primates (NHPs). NHPs received either the dose planned for patients adjusted to the brain volume ratio between child and NHP (1×dose, 1.1×1011 vg/hemisphere, unilateral or bilateral injection) or 5-fold this dose (5×dose, 5.5×1011 vg/hemisphere, bilateral injection). NHPs were subjected to clinical, biological, and brain imaging observations and were euthanized 7 or 90 days after injection. There was no toxicity based on clinical and biological parameters, nor treatment-related histological findings in peripheral organs. A neuroinflammatory process correlating with brain MRI T2 hypersignals was observed in the brain 90 days after administration of the 5×dose, but was absent or minimal after administration of the 1×dose. Antibody response to AAVrh.10 and hARSA was detected, without correlation with brain lesions. After injection of the 1×dose, AAVrh.10-hARSA vector was detected in a large part of the injected hemisphere, while ARSA activity exceeded the normal endogenous activity level by 14-31%. Consistently with other reports, vector genome was detected in off-target organs such as liver, spleen, lymph nodes, or blood, but not in gonads. Importantly, AAVrh.10-hARSA vector was no longer detectable in urine at day 7. Our data demonstrate requisite safe and effective profile for intracerebral AAVrh.10-hARSA delivery in NHPs, supporting its clinical use in children affected with MLD.

Original languageEnglish
Pages (from-to)113-124
Number of pages12
JournalHuman Gene Therapy Clinical Development
Volume26
Issue number2
DOIs
Publication statusPublished - 1 Jun 2015
Externally publishedYes

Fingerprint

Metachromatic Leukodystrophy
Cerebroside-Sulfatase
Genetic Therapy
Primates
Safety
Injections
Brain
Lysosomal Storage Diseases
Peripheral Nervous System
Gonads
Demyelinating Diseases
Neuroimaging
Antibody Formation
Spleen
Central Nervous System
Lymph Nodes
Urine
Genome
Liver
Enzymes

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

Intracerebral Gene Therapy Using AAVrh.10-hARSA Recombinant Vector to Treat Patients with Early-Onset Forms of Metachromatic Leukodystrophy : Preclinical Feasibility and Safety Assessments in Nonhuman Primates. / Zerah, Michel; Piguet, Françoise; Colle, Marie Anne; Raoul, Sylvie; Deschamps, Jack Yves; Deniaud, Johan; Gautier, Benoit; Toulgoat, Frédérique; Bieche, Ivan; Laurendeau, Ingrid; Sondhi, Dolan; Souweidane, Mark M.; Cartier-Lacave, Nathalie; Moullier, Philippe; Crystal, Ronald; Roujeau, Thomas; Sevin, Caroline; Aubourg, Patrick.

In: Human Gene Therapy Clinical Development, Vol. 26, No. 2, 01.06.2015, p. 113-124.

Research output: Contribution to journalArticle

Zerah, M, Piguet, F, Colle, MA, Raoul, S, Deschamps, JY, Deniaud, J, Gautier, B, Toulgoat, F, Bieche, I, Laurendeau, I, Sondhi, D, Souweidane, MM, Cartier-Lacave, N, Moullier, P, Crystal, R, Roujeau, T, Sevin, C & Aubourg, P 2015, 'Intracerebral Gene Therapy Using AAVrh.10-hARSA Recombinant Vector to Treat Patients with Early-Onset Forms of Metachromatic Leukodystrophy: Preclinical Feasibility and Safety Assessments in Nonhuman Primates', Human Gene Therapy Clinical Development, vol. 26, no. 2, pp. 113-124. https://doi.org/10.1089/humc.2014.139
Zerah, Michel ; Piguet, Françoise ; Colle, Marie Anne ; Raoul, Sylvie ; Deschamps, Jack Yves ; Deniaud, Johan ; Gautier, Benoit ; Toulgoat, Frédérique ; Bieche, Ivan ; Laurendeau, Ingrid ; Sondhi, Dolan ; Souweidane, Mark M. ; Cartier-Lacave, Nathalie ; Moullier, Philippe ; Crystal, Ronald ; Roujeau, Thomas ; Sevin, Caroline ; Aubourg, Patrick. / Intracerebral Gene Therapy Using AAVrh.10-hARSA Recombinant Vector to Treat Patients with Early-Onset Forms of Metachromatic Leukodystrophy : Preclinical Feasibility and Safety Assessments in Nonhuman Primates. In: Human Gene Therapy Clinical Development. 2015 ; Vol. 26, No. 2. pp. 113-124.
@article{1f79ff8a7d094a7c9c957051823c6434,
title = "Intracerebral Gene Therapy Using AAVrh.10-hARSA Recombinant Vector to Treat Patients with Early-Onset Forms of Metachromatic Leukodystrophy: Preclinical Feasibility and Safety Assessments in Nonhuman Primates",
abstract = "No treatment is available for early-onset forms of metachromatic leukodystrophy (MLD), a lysosomal storage disease caused by autosomal recessive defect in arylsulfatase A (ARSA) gene causing severe demyelination in central and peripheral nervous systems. We have developed a gene therapy approach, based on intracerebral administration of AAVrh.10-hARSA vector, coding for human ARSA enzyme. We have previously demonstrated potency of this approach in MLD mice lacking ARSA expression. We describe herein the preclinical efficacy, safety, and biodistribution profile of intracerebral administration of AAVrh.10-hARSA to nonhuman primates (NHPs). NHPs received either the dose planned for patients adjusted to the brain volume ratio between child and NHP (1×dose, 1.1×1011 vg/hemisphere, unilateral or bilateral injection) or 5-fold this dose (5×dose, 5.5×1011 vg/hemisphere, bilateral injection). NHPs were subjected to clinical, biological, and brain imaging observations and were euthanized 7 or 90 days after injection. There was no toxicity based on clinical and biological parameters, nor treatment-related histological findings in peripheral organs. A neuroinflammatory process correlating with brain MRI T2 hypersignals was observed in the brain 90 days after administration of the 5×dose, but was absent or minimal after administration of the 1×dose. Antibody response to AAVrh.10 and hARSA was detected, without correlation with brain lesions. After injection of the 1×dose, AAVrh.10-hARSA vector was detected in a large part of the injected hemisphere, while ARSA activity exceeded the normal endogenous activity level by 14-31{\%}. Consistently with other reports, vector genome was detected in off-target organs such as liver, spleen, lymph nodes, or blood, but not in gonads. Importantly, AAVrh.10-hARSA vector was no longer detectable in urine at day 7. Our data demonstrate requisite safe and effective profile for intracerebral AAVrh.10-hARSA delivery in NHPs, supporting its clinical use in children affected with MLD.",
author = "Michel Zerah and Fran{\cc}oise Piguet and Colle, {Marie Anne} and Sylvie Raoul and Deschamps, {Jack Yves} and Johan Deniaud and Benoit Gautier and Fr{\'e}d{\'e}rique Toulgoat and Ivan Bieche and Ingrid Laurendeau and Dolan Sondhi and Souweidane, {Mark M.} and Nathalie Cartier-Lacave and Philippe Moullier and Ronald Crystal and Thomas Roujeau and Caroline Sevin and Patrick Aubourg",
year = "2015",
month = "6",
day = "1",
doi = "10.1089/humc.2014.139",
language = "English",
volume = "26",
pages = "113--124",
journal = "Human gene therapy. Clinical development",
issn = "2324-8637",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Intracerebral Gene Therapy Using AAVrh.10-hARSA Recombinant Vector to Treat Patients with Early-Onset Forms of Metachromatic Leukodystrophy

T2 - Preclinical Feasibility and Safety Assessments in Nonhuman Primates

AU - Zerah, Michel

AU - Piguet, Françoise

AU - Colle, Marie Anne

AU - Raoul, Sylvie

AU - Deschamps, Jack Yves

AU - Deniaud, Johan

AU - Gautier, Benoit

AU - Toulgoat, Frédérique

AU - Bieche, Ivan

AU - Laurendeau, Ingrid

AU - Sondhi, Dolan

AU - Souweidane, Mark M.

AU - Cartier-Lacave, Nathalie

AU - Moullier, Philippe

AU - Crystal, Ronald

AU - Roujeau, Thomas

AU - Sevin, Caroline

AU - Aubourg, Patrick

PY - 2015/6/1

Y1 - 2015/6/1

N2 - No treatment is available for early-onset forms of metachromatic leukodystrophy (MLD), a lysosomal storage disease caused by autosomal recessive defect in arylsulfatase A (ARSA) gene causing severe demyelination in central and peripheral nervous systems. We have developed a gene therapy approach, based on intracerebral administration of AAVrh.10-hARSA vector, coding for human ARSA enzyme. We have previously demonstrated potency of this approach in MLD mice lacking ARSA expression. We describe herein the preclinical efficacy, safety, and biodistribution profile of intracerebral administration of AAVrh.10-hARSA to nonhuman primates (NHPs). NHPs received either the dose planned for patients adjusted to the brain volume ratio between child and NHP (1×dose, 1.1×1011 vg/hemisphere, unilateral or bilateral injection) or 5-fold this dose (5×dose, 5.5×1011 vg/hemisphere, bilateral injection). NHPs were subjected to clinical, biological, and brain imaging observations and were euthanized 7 or 90 days after injection. There was no toxicity based on clinical and biological parameters, nor treatment-related histological findings in peripheral organs. A neuroinflammatory process correlating with brain MRI T2 hypersignals was observed in the brain 90 days after administration of the 5×dose, but was absent or minimal after administration of the 1×dose. Antibody response to AAVrh.10 and hARSA was detected, without correlation with brain lesions. After injection of the 1×dose, AAVrh.10-hARSA vector was detected in a large part of the injected hemisphere, while ARSA activity exceeded the normal endogenous activity level by 14-31%. Consistently with other reports, vector genome was detected in off-target organs such as liver, spleen, lymph nodes, or blood, but not in gonads. Importantly, AAVrh.10-hARSA vector was no longer detectable in urine at day 7. Our data demonstrate requisite safe and effective profile for intracerebral AAVrh.10-hARSA delivery in NHPs, supporting its clinical use in children affected with MLD.

AB - No treatment is available for early-onset forms of metachromatic leukodystrophy (MLD), a lysosomal storage disease caused by autosomal recessive defect in arylsulfatase A (ARSA) gene causing severe demyelination in central and peripheral nervous systems. We have developed a gene therapy approach, based on intracerebral administration of AAVrh.10-hARSA vector, coding for human ARSA enzyme. We have previously demonstrated potency of this approach in MLD mice lacking ARSA expression. We describe herein the preclinical efficacy, safety, and biodistribution profile of intracerebral administration of AAVrh.10-hARSA to nonhuman primates (NHPs). NHPs received either the dose planned for patients adjusted to the brain volume ratio between child and NHP (1×dose, 1.1×1011 vg/hemisphere, unilateral or bilateral injection) or 5-fold this dose (5×dose, 5.5×1011 vg/hemisphere, bilateral injection). NHPs were subjected to clinical, biological, and brain imaging observations and were euthanized 7 or 90 days after injection. There was no toxicity based on clinical and biological parameters, nor treatment-related histological findings in peripheral organs. A neuroinflammatory process correlating with brain MRI T2 hypersignals was observed in the brain 90 days after administration of the 5×dose, but was absent or minimal after administration of the 1×dose. Antibody response to AAVrh.10 and hARSA was detected, without correlation with brain lesions. After injection of the 1×dose, AAVrh.10-hARSA vector was detected in a large part of the injected hemisphere, while ARSA activity exceeded the normal endogenous activity level by 14-31%. Consistently with other reports, vector genome was detected in off-target organs such as liver, spleen, lymph nodes, or blood, but not in gonads. Importantly, AAVrh.10-hARSA vector was no longer detectable in urine at day 7. Our data demonstrate requisite safe and effective profile for intracerebral AAVrh.10-hARSA delivery in NHPs, supporting its clinical use in children affected with MLD.

UR - http://www.scopus.com/inward/record.url?scp=84964695778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964695778&partnerID=8YFLogxK

U2 - 10.1089/humc.2014.139

DO - 10.1089/humc.2014.139

M3 - Article

VL - 26

SP - 113

EP - 124

JO - Human gene therapy. Clinical development

JF - Human gene therapy. Clinical development

SN - 2324-8637

IS - 2

ER -